Optimize drug therapy and monitor patient adherence. Useful for ruling out barbiturate exposure. For follow-up testing of a presumptive result, Barbiturates, Urine Quantitative (2012213) is preferred.
Quantitative Gas Chromatography-Mass Spectrometry/Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Tue, Thu, Sat
New York DOH Approval Status
Gray (sodium fluoride/potassium oxalate). Also acceptable: Plain red, green (sodium heparin), lavender (EDTA), or pink (K2EDTA).
Separate serum or plasma from cells ASAP or within 2 hours of collection. Transfer 3.5 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 1.5 mL)
Separator tubes. Plasma or whole blood collected in lt. blue (sodium citrate). Specimens exposed to repeated freeze/thaw cycles. Hemolyzed specimens.
After separation from cells: Ambient: 1 week; Refrigerated: 2 weeks; Frozen: 3 years
Methodology: Quantitative Gas Chromatography-Mass Spectrometry/Quantitative Liquid Chromatography-Tandem Mass Spectrometry.
Positive cutoff: 50 ng/mL
For medical purposes only; not valid for forensic use.
The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, or limitations of testing. The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
80345 (Alt code: G0480)
|Component Test Code*||Component Chart Name||LOINC|
|2012202||Phenobarbital, S/P, Quant||3948-7|
|2012203||Butalbital, S/P, Quant||6895-7|
|2012204||Pentobarbital, S/P, Quant||3924-8|
- Pain Management